Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 24, 2022

Margetuximab vs Trastuzumab in Patients With Previously Treated HER2+ Advanced Breast Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
J. Clin. Oncol 2022 Nov 04;[EPub Ahead of Print], HS Rugo, SA Im, F Cardoso, J Cortes, G Curigliano, A Musolino, MD Pegram, T Bachelot, GS Wright, C Saura, S Escrivá-de-Romaní, M De Laurentiis, GN Schwartz, TJ Pluard, F Ricci, WR Gwin, C Levy, U Brown-Glaberman, JM Ferrero, M de Boer, SB Kim, K Petráková, DA Yardley, O Freedman, EH Jakobsen, EN Gal-Yam, R Yerushalmi, PA Fasching, PA Kaufman, EJ Ashley, R Perez-Olle, S Hong, MK Rosales, WJ Gradishar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading